Ballicules.com

Varenicline

CHANTIX

What it isPartial agonist at the alpha-4-beta-2 nicotinic receptor; smoking cessation.

Why this oneThe most effective single agent for quitting, because partial agonism both reduces craving and blunts the reward of smoking.

What limits itNausea is common and dose-related. Start one to two weeks before the quit date; renally adjusted.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Smoking cessationAdults0.5 mg QD (days 1–3), then 0.5 mg BID (days 4–7)1 mg BID for 12 weeks (may add 12 more weeks)1 mg BID

Titration Titrate over the first week before reaching 1 mg BID.

Renal Severe impairment (CrCl <30 mL/min): start 0.5 mg QD, titrate to 0.5 mg BID. ESRD on hemodialysis: max 0.5 mg QD.

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy No suggested increased risk of major birth defects vs. women who smoke; smoking itself carries fetal risk.

Lactation Undefined

NO BOXED WARNINGS

Principal riskNausea; vivid dreams

Cost, est. cash$5–$150/month

Generic entry2021

Classes and tags

Clinical profile

Therapeutic safety burden0 / 4
Overdose danger0 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Mechanism of action: Varenicline ballicule

Varenicline ballicule: receptor binding, kinetics and half-life diagram

Open Varenicline in the interactive console ↗

Memory aids: mascots and interaction avatars

Varenicline CHANTIX mascot mnemonic cartoon
“Very inclined Chanting”
Varenicline Box: minimal PK interactions avatar
Box: minimal PK interactions

Open Varenicline in the interactive console ↗